Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Down 20.5% in September

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 235,100 shares, a drop of 20.5% from the August 31st total of 295,900 shares. Currently, 2.7% of the company’s shares are sold short. Based on an average daily trading volume, of 289,100 shares, the short-interest ratio is presently 0.8 days.

Petros Pharmaceuticals Trading Up 4.2 %

PTPI traded up $0.01 during mid-day trading on Friday, reaching $0.35. The stock had a trading volume of 33,941 shares, compared to its average volume of 577,828. The stock has a market capitalization of $2.45 million, a P/E ratio of -0.05 and a beta of 2.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.26 and a current ratio of 1.40. The firm’s fifty day simple moving average is $0.36 and its two-hundred day simple moving average is $0.59. Petros Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.27.

Petros Pharmaceuticals (NASDAQ:PTPI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The firm had revenue of $1.42 million during the quarter.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).